Log in to search using one of your social media accounts:

 

Discussion

Dr Y. Colson (Boston, Mass). You have nicely investigated the potential role of MMP-12 in lung cancer progression, mainly invasion, and you have postulated a role for it as a therapeutic target. You have shown roughly 3 aspects of what you have investigated, quite elegantly, actually. First is in characterizing MMP-12 expression and localization in tissue samples, and in gene array databases you have ubiquitous expression in NSCLC with the exception of the bronchoalveolar, and the association of MMP-12 mRNA in tumors with reduced survival.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

In this study, deformable registration (DIR) and dose accumulation (DA) were used to calculate the accumulated dose received over the course of treatment.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Tags: Posters Source Type: research
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Publication date: April 2018 Source:Biomedicine & Pharmacotherapy, Volume 100 Author(s): Shixiu Feng, Zhenzhen Wang, Min Zhang, Xiaohui Zhu, Zhanjun Ren HG30, a tetrahydroanthraquinone compound isolated from the roots of Prismatomeris connate, was previously shown to inhibit the proliferation of A549 cells. The aim of this study was to evaluate the antitumor activity of HG30 in two non-small cell lung cancer cell lines, A549 and H1299, and to explore potential underlying mechanisms. In cell viability and colony formation assays, HG30 treatment suppressed the proliferation and number of colonies formed by A549 and H129...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionsThe use of 8 –10 fractions schedule HT-SBRT for lung malignancies results in high LC and OS rates with minimal toxicities reported.
Source: La Radiologia Medica - Category: Radiology Source Type: research
In this study, we investigated the functional role and prognostic value of spindle pole body component 25 (SPC25) in non-small cell lung cancer (NSCLC). SPC25 expression profile in lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and normal lung tissues was examined by using data from the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA). LUAD A549 cells and LUSC H520 cells were used to investigate the influence of SPC25 on cancer stem cell (CSC) properties in terms of the proportion of CD133+ cells, tumorsphere formation and CSC markers, including CD133, ALDH1 and Sox2. Data mining was also perfo...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The immunotherapy becomes the first treatment approved to reduce the risk for progression in hard-to-treat stage III non-small cell lung cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
(Reuters) - The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's, immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves drug to reduce the risk of stage III non-small cell lung cancer progressing
Source: Food and Drug Administration - Category: American Health Source Type: news
Conclusions: CT-guided 125I seed implantation combined with chemotherapy is an effective, minimally invasive method for the treatment of stage III NSCLC. Furthermore, hemoglobin levels before treatment, D100, and the maximum diameter of the tumor may be prognostic factors in patients with NSCLC treated sequentially with radiotherapy and chemotherapy. PMID: 29441096 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Publication date: 10 May 2018 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 153 Author(s): Cheng Cui, Pei Hu, Ji Jiang, Fansheng Kong, Hong Luo, Qian Zhao CT-707, a mutant-selective inhibitor of an important cancer target, anaplastic lymphoma kinase (ALK), is designed to be a targeted therapeutic agent for non-small cell lung cancer (NSCLC) patients harboring ALK active and crizotinib resistant mutations. A rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS) method was developed and validated for the determination of CT-707 and its two metabolites (M1 ...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Databases & Libraries | Genetics | Heart | Lung Cancer | Non-Small Cell Lung Cancer